Item 3.01    Notice of Delisting or Failure to Satisfy a Continued Listing Rule
             or Standard; Transfer of Listing.



On April 16, 2021, Arcus Biosciences, Inc. notified the New York Stock Exchange that the Arcus Board of Directors determined that David Lacey, an independent director of Arcus and a member of the Audit Committee of the Board of Directors of Arcus, did not meet the heightened independence requirements for service on the Audit Committee as required by Securities and Exchange Commission Rule 10A-3 and NYSE Rule 303A.06 due to his compensation for serving on Arcus's scientific advisory board. Upon making this determination, the Arcus Board of Directors appointed Andrew Perlman to the Audit Committee in place of Dr. Lacey and appointed Dr. Lacey to the Nominating and Corporate Governance Committee in place of Dr. Perlman.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses